Skip to main
ATAI
ATAI logo

ATAI Stock Forecast & Price Target

ATAI Analyst Ratings

Based on 4 analyst ratings
Strong Buy
Strong Buy 75%
Buy 25%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

ATAI Life Sciences NV is experiencing a positive outlook due to promising clinical data supporting its drug candidate BPL-003, which has shown improved mean MADRS scores and a doubled remission rate after the second dose, indicating significant therapeutic potential for treatment-resistant depression. The company's innovative approach and anticipated market entry strategy could allow BPL-003 to capture an estimated 20% market share by 2035, highlighting its competitive positioning within the mental health treatment landscape. Additionally, the recent strong stock performance, along with expectations of continued favorable data and potential FDA alignment, reinforces the likelihood of further upside for the company’s equity value.

Bears say

The financial outlook for ATAI Life Sciences, NV, appears negative primarily due to the decline in efficacy observed in its Phase 2b clinical trial data, with significant deterioration in patient outcomes measured at different time points. Specifically, the company’s treatment showed reduced effectiveness over time, with a placebo-adjusted change in the Montgomery-Åsberg Depression Rating Scale (MADRS) of only -3.6 at week 6, which underperformed compared to competitors like Spravato and raised concerns about its competitiveness in the market. Furthermore, the limited safety data from earlier studies, particularly regarding potential risks associated with two-dose induction protocols, raises additional uncertainties about the robustness of ATAI's therapeutic options.

ATAI has been analyzed by 4 analysts, with a consensus rating of Strong Buy. 75% of analysts recommend a Strong Buy, 25% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Atai Life Sciences BV and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Atai Life Sciences BV (ATAI) Forecast

Analysts have given ATAI a Strong Buy based on their latest research and market trends.

According to 4 analysts, ATAI has a Strong Buy consensus rating as of Nov 4, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $13.75, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $13.75, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Atai Life Sciences BV (ATAI)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.